NCT00377429 - Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions

Ovarian Cancer

Interventions

DRUG

catumaxomab

Catumaxomab administered as four 3-hour, constant-rate, intraperitoneal (IP) infusions of 10, 20, 50, 150 microgram (mcg).

Trial Locations (12)

Magee-Women Hospital of UPMC, Pittsburgh

Wake Forest University Health Sciences, Winston-Salem

South Carolina Oncology Associates, Columbia

Florida Hospital Cancer Institute, Orlando

James Graham Brown Cancer Center, Louisville

Michiana Hematology Oncology P.C., South Bend

Gynecologic Oncology - Hinsdale, Hinsdale

Arizona Cancer Center, Tucson

University of New Mexico, Albuquerque

Stanford University of Obstetrics and Gynecology, Stanford

Massachusetts General Hospital, Boston

Dartmouth-Hitchcock Medical Center, Lebanon